On Tuesday, Madrigal Pharmaceuticals received an upgrade to its Relative Strength (RS) Rating, from 62 to 71.
Can You Really Time The Stock Market?
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks compares to other publicly traded companies.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they launch their largest price moves. See if Madrigal Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Madrigal Pharmaceuticals is building a consolidation with a 377.46 buy point. See if the stock can break out in heavy trade.
Madrigal Pharmaceuticals showed 0% EPS growth in its most recent report, while sales growth came in at 0%. The company is expected to report its latest numbers on or around Aug. 6.
The company holds the No. 95 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
